ProCE Banner Activity

CME

An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

Video

Watch this on-demand webcast from an ASH satellite symposium on the use of current and emerging therapies for patients with myelodysplastic syndromes, including discussions on managing disease-related symptoms, planning therapy by risk status, treatment for higher-risk myelodysplastic syndromes, and ongoing clinical trials.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 27, 2023

Expiration: January 26, 2024

No longer available for credit.

Share

Faculty

María Díez Campelo

María Díez Campelo, MD, PhD

Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

Rami Komrokji

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with MDS.

Learning Objectives

  • Integrate novel therapeutic options for managing MDS-related symptoms, which may include anemia, cytopenia, thrombocytopenia, and/or neutropenia
  • Plan therapeutic strategies using available and emerging treatment options for patients with lower-, intermediate-, or high-risk MDS based on expert recommendations and available clinical evidence
  • Plan evidence-based therapeutic strategies for patients with relapsed/refractory disease
  • Identify patients eligible for enrollment on clinical trials investigating novel therapeutic approaches for treating and managing MDS

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

María Díez Campelo, MD, PhD

Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

María Díez Campelo, MD, PhD: consultant/advisor/speaker: Blueprint, Bristol Myers Squibb, Novartis, Takeda.

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, CTI BioPharma, Geron, Gilead Sciences, Jazz, Novartis, PharmaEssentia, Servier, Taiho, Takeda.

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MPH: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, Trovagene; consultant: Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, Tyme.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 27, 2023, through January 26, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this program is to improve the knowledge and competence of learners on current and emerging treatment options and the latest clinical data on lower-risk, intermediate-risk, and high-risk MDS.